Literature DB >> 31195225

The role of complement in antibody mediated transplant rejection.

Joshua M Thurman1, Sarah E Panzer2, Moglie Le Quintrec3.   

Abstract

Antibody mediated transplant rejection (AMR) is a major cause of long-term allograft failure, and currently available treatments are of limited efficacy for treating the disease. AMR is caused by donor specific antibodies (DSA) that bind to antigens within the transplanted organ. DSA usually activate the classical pathway of complement within the allograft, and complement activation is believed to be an important cause of tissue injury in AMR. Several new clinical assays may improve our ability to identify patients at risk of AMR. Complement inhibitory drugs have also been tested in selected patients and in small series. Better understanding of the role of complement activation in the pathogenesis of AMR will likely improve our ability to diagnose the disease and to develop novel treatments.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody mediated rejection; Complement; Immunoglobulin; Transplant

Mesh：

Substances：

Year:  2019        PMID： 31195225      PMCID： PMC6646053          DOI： 10.1016/j.molimm.2019.06.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


  68 in total

1.  The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.

Authors:  J E Locke; C M Magro; A L Singer; D L Segev; M Haas; A T Hillel; K E King; E Kraus; L M Lees; J K Melancon; Z A Stewart; D S Warren; A A Zachary; R A Montgomery
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

2.  Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation.

Authors:  K S Kilgore; E Schmid; T P Shanley; C M Flory; V Maheswari; N L Tramontini; H Cohen; P A Ward; H P Friedl; J S Warren
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

3.  Antibody-mediated rejection: New approaches in prevention and management.

Authors:  R A Montgomery; A Loupy; D L Segev
Journal:  Am J Transplant       Date:  2018-01       Impact factor: 8.086

4.  Endothelial cell activation by pore-forming structures: pivotal role for interleukin-1alpha.

Authors:  S Saadi; R A Holzknecht; C P Patte; J L Platt
Journal:  Circulation       Date:  2000-04-18       Impact factor: 29.690

5.  Complement factor h limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness.

Authors:  Jessy J Alexander; Matthew C Pickering; Mark Haas; Iyabo Osawe; Richard J Quigg
Journal:  J Am Soc Nephrol       Date:  2004-12-01       Impact factor: 10.121

6.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

7.  Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Authors:  Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

8.  Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion.

Authors:  Nils Lachmann; Kremena Todorova; Harald Schulze; Constanze Schönemann
Journal:  Transfus Med Hemother       Date:  2013-05-08       Impact factor: 3.747

9.  ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis.

Authors:  Annelies E de Weerd; Michiel G H Betjes
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-16       Impact factor: 8.237

10.  One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.

Authors:  Bénédicte Sautenet; Gilles Blancho; Mathias Büchler; Emmanuel Morelon; Olivier Toupance; Benoit Barrou; Didier Ducloux; Valérie Chatelet; Bruno Moulin; Caroline Freguin; Marc Hazzan; Philippe Lang; Christophe Legendre; Pierre Merville; Georges Mourad; Christine Mousson; Claire Pouteil-Noble; Raj Purgus; Jean-Philippe Rerolle; Johnny Sayegh; Pierre-François Westeel; Philippe Zaoui; Hedia Boivin; Amélie Le Gouge; Yvon Lebranchu
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939
View more
  5 in total

Review 1.  The Role of Complement in Organ Transplantation.

Authors:  Monica Grafals; Joshua M Thurman
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

2.  Pre-transplant Transcriptional Signature in Peripheral Blood Mononuclear Cells of Acute Renal Allograft Rejection.

Authors:  Wenyu Xiang; Shuai Han; Cuili Wang; Hongjun Chen; Lingling Shen; Tingting Zhu; Kai Wang; Wenjie Wei; Jing Qin; Nelli Shushakova; Song Rong; Hermann Haller; Hong Jiang; Jianghua Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-07

3.  Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.

Authors:  Gesa Tiller; Rosa G M Lammerts; Jessy J Karijosemito; Firas F Alkaff; Arjan Diepstra; Robert A Pol; Anita H Meter-Arkema; Marc A Seelen; Marius C van den Heuvel; Bouke G Hepkema; Mohamed R Daha; Jacob van den Born; Stefan P Berger
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

4.  C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

Authors:  Seline A Zwarthoff; Kevin Widmer; Annemarie Kuipers; Jürgen Strasser; Maartje Ruyken; Piet C Aerts; Carla J C de Haas; Deniz Ugurlar; Maurits A den Boer; Gestur Vidarsson; Jos A G van Strijp; Piet Gros; Paul W H I Parren; Kok P M van Kessel; Johannes Preiner; Frank J Beurskens; Janine Schuurman; Daniel Ricklin; Suzan H M Rooijakkers
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

5.  Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.

Authors:  Nick S Laursen; Dennis V Pedersen; Heidi Gytz; Alessandra Zarantonello; Jens Magnus Bernth Jensen; Annette G Hansen; Steffen Thiel; Gregers R Andersen
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.